The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.
NCT ID: NCT06765850
Last Updated: 2025-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2022-07-04
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
NCT06863870
Metabolic Phenotypes in Melanoma
NCT05570227
Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy
NCT02133222
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
NCT01205815
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden University Hospital
Exclusion Criteria
* Lack of capacity to consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Carl Gustav Carus
OTHER
Technische Universität Dresden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Frank Friedrich Gellrich
Senior Physician in Dermatology and Medical Tumor Therapy, Principal Investigator, MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Carl Gustav Carus
Dresden, Saxony, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Frank Friedrich Gellrich, Dr. med.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Melanomix
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.